Import from '@womanrx/components'

Duavee Regulatory Status: US, EU, Canada, and UK, What Every Woman Needs to Know

What Is Duavee and How Does It Work?

Duavee combines two separate drugs into one daily oral tablet: conjugated estrogens (CE) and bazedoxifene (BZA). The estrogen component relieves menopausal symptoms. Bazedoxifene, a selective estrogen receptor modulator (SERM), protects the uterine lining from estrogen-driven overgrowth, which is exactly the job a progestin would normally do in standard hormone therapy.

The TSEC Concept

The pairing is called a tissue-selective estrogen complex (TSEC). The idea is that a SERM can act as an estrogen antagonist in the uterus and breast while allowing estrogen to work in the brain (reducing hot flashes) and bone (preserving density). This is meaningfully different from adding a progestin, because progestins have their own side-effect profile including mood changes, bloating, and, in some formulations, a small increase in breast cancer risk with long-term use.

Bazedoxifene binds estrogen receptors in the endometrium and blocks CE-driven proliferation. In the SMART-1 trial, endometrial hyperplasia rates at 24 months were under 1% with CE 0.45 mg/BZA 20 mg, comparable to placebo, which was the key safety data the FDA required before approval.

Receptor-Level Pharmacology

Bazedoxifene has high binding affinity for both estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ). In uterine tissue, it acts as a full antagonist. In bone, it acts as a partial agonist, which is why CE/BZA also carries an indication for prevention of postmenopausal osteoporosis in the United States. The estrogen component itself is the same conjugated equine estrogen mixture used in Premarin for decades.

Why This Matters for Women Who Cannot Tolerate Progestins

Some postmenopausal women experience significant side effects on progestins, including depressive symptoms, fluid retention, or worsening migraines. For these women, CE/BZA offers a clinically distinct option that still provides uterine protection, without adding a progestogen to the regimen.

FDA Approval: United States

The FDA approved Duavee on October 3, 2013, for two indications in postmenopausal women who have a uterus: moderate-to-severe vasomotor symptoms (hot flashes and night sweats) and prevention of postmenopausal osteoporosis. The FDA prescribing information specifies the approved dose as CE 0.45 mg / BZA 20 mg once daily, oral tablet.

The SMART Trial Program

The approval rested on the SMART (Selective estrogens, Menopause, And Response to Therapy) trials, a series of five randomized controlled trials. SMART-2 is the most cited efficacy paper. It enrolled 318 postmenopausal women with at least seven moderate-to-severe hot flashes per day at baseline. At 12 weeks, CE 0.45 mg/BZA 20 mg reduced mean daily hot flash frequency by 74% versus 51% for placebo. That is a statistically significant and clinically meaningful gap.

SMART-1 was the safety backbone: 2,064 postmenopausal women followed for up to 24 months, with endometrial biopsy data confirming that CE/BZA did not stimulate the endometrium. No cases of endometrial hyperplasia were found in the CE 0.45 mg/BZA 20 mg arm versus 0% in placebo and 3.7% in the CE-alone arm, validating bazedoxifene's protective role.

FDA-Labeled Contraindications and Warnings

The FDA label carries the same Black Box Warning that applies to all estrogen-containing therapies:

• Endometrial cancer risk (mitigated by BZA in this formulation)
• Cardiovascular events (stroke, DVT/PE)
• Probable dementia in women aged 65 and older (from the WHI Memory Study)

The label also warns against use in women with undiagnosed abnormal uterine bleeding, known or suspected breast cancer, active or prior VTE, and active arterial thromboembolic disease.

EMA Approval: European Union

The European Medicines Agency approved conjugated estrogens/bazedoxifene under the brand name Duavive in December 2014. The approved indication in the EU is narrower than the US label: Duavive is indicated for treatment of estrogen deficiency symptoms in postmenopausal women with a uterus for whom treatment with progestogen-containing therapy is not considered appropriate. The EU label does not include the osteoporosis prevention indication that appears in the US prescribing information.

Why the EU Indication Is Worded Differently

The EMA's Committee for Medicinal Products for Human Use (CHMP) took a more conservative framing. Rather than approving it as a first-line alternative to combined HRT, the EU indication positions Duavive specifically for women where a progestogen is not appropriate. This language reflects the EMA's view of the existing evidence base: the SMART trials were strong for symptom relief and endometrial safety, but long-term cardiovascular and breast outcomes data in this specific TSEC population are still accumulating.

EU Member State Availability

EMA approval grants a centralized marketing authorization valid across all EU member states, but commercial availability varies by country depending on national reimbursement decisions. Pfizer has marketed Duavive in several EU countries including Germany, France, and the Netherlands. Women in the EU should verify current formulary status with their national health authority, as availability can change without affecting the EMA license itself.

Canada: Not Approved

Health Canada has not approved Duavee or Duavive as of January 2025. Conjugated estrogens alone (Premarin) and several other hormone therapy options are available in Canada, but the CE/BZA fixed-dose combination does not appear on the Health Canada Drug Product Database as an authorized product.

Canadian women asking about this drug may encounter it through cross-border discussions or US-based telehealth platforms. Obtaining an unapproved drug through a Canadian physician is theoretically possible via Health Canada's Special Access Program (SAP), which allows access to drugs not approved in Canada for patients with serious or life-threatening conditions. However, moderate-to-severe menopausal symptoms would need a compelling clinical justification to meet SAP criteria, and approval is not guaranteed.

For Canadian women who cannot tolerate progestogens, the Society of Obstetricians and Gynaecologists of Canada (SOGC) 2021 menopause guidelines acknowledge the TSEC concept and the SMART trial data, but they do not have a domestically approved product to recommend. Micronized progesterone (Prometrium) or levonorgestrel-releasing IUD are the SOGC's preferred uterine protection alternatives for estrogen therapy.

United Kingdom: Not Approved

The Medicines and Healthcare products Regulatory Agency (MHRA) has not approved Duavee or Duavive for use in the UK. This is a post-Brexit regulatory divergence: while the EMA granted centralized approval for Duavive in 2014, the UK did not adopt this approval after leaving the EU, and Pfizer has not submitted a separate Marketing Authorisation Application to the MHRA for this product.

NICE guideline NG23 on menopause covers hormone therapy options available in the UK and does not include CE/BZA because it has no UK marketing authorization. UK prescribers cannot legally prescribe it on the NHS. A private specialist could theoretically obtain it as an unlicensed medicine ("specials" route), but this is uncommon, carries extra regulatory burden, and is not a routine clinical pathway.

Women in the UK seeking alternatives to progestogen-based HRT have access to the levonorgestrel-releasing intrauterine system (Mirena) for uterine protection alongside transdermal or oral estrogen, or to estrogen-only therapy if they have had a hysterectomy.

Mechanism Deep Dive: How CE/BZA Differs from Conventional HRT

Standard combined hormone therapy for a woman with a uterus requires adding a progestogen to prevent estrogen-driven endometrial hyperplasia. CE/BZA replaces that progestogen with a SERM. The pharmacological logic depends on bazedoxifene's ability to be simultaneously:

• An estrogen antagonist in uterine and breast tissue
• An agonist (or neutral) in bone and the cardiovascular system
• An agonist in the central nervous system pathways that regulate temperature

Breast Tissue Effects

This is where CE/BZA data are still thin. Bazedoxifene was designed to be anti-estrogenic in breast tissue, and animal model data support this. The SMART-5 trial reported no increase in breast density at 12 months with CE/BZA compared with placebo, whereas CE plus medroxyprogesterone acetate (MPA) increased breast density by a statistically significant margin. Breast density is a surrogate for breast cancer risk, not a direct endpoint. Long-term breast cancer incidence data specific to CE/BZA do not yet exist from a dedicated trial.

A practical framework for thinking about CE/BZA's breast profile: bazedoxifene's class (third-generation SERM) includes raloxifene, which has demonstrated breast cancer risk reduction in high-risk women in the STAR trial. CE/BZA has not been tested for that indication. The absence of increased breast density is reassuring but not equivalent to proven breast safety over a 10-to-20-year horizon.

Bone Effects

SMART-5 also showed that CE 0.45 mg/BZA 20 mg preserved lumbar spine bone mineral density (BMD) significantly better than placebo at 12 months, supporting the osteoporosis prevention indication in the US label. Bazedoxifene alone is approved in the EU as a standalone osteoporosis treatment (Conbriza), so its bone-protective mechanism is separately established.

Fat Distribution and Metabolic Health

Women gain visceral fat preferentially after menopause, driven partly by estrogen withdrawal. Standard estrogen therapy tends to attenuate this shift. CE/BZA appears to share this benefit: SMART-5 data showed significantly smaller increases in total body fat and trunk fat in women taking CE/BZA versus placebo over 12 months. This is clinically relevant for postmenopausal women with metabolic syndrome or those at elevated type 2 diabetes risk, though CE/BZA is not approved for metabolic indications.

Who This Drug Is Right For (and Who It Is Not)

CE/BZA is a postmenopause-specific drug. It has no role in perimenopause, reproductive years, pregnancy, or lactation.

Women Who May Benefit Most

• Postmenopausal women with an intact uterus who have moderate-to-severe hot flashes or night sweats
• Women who have trialed progestogen-based HRT and experienced significant side effects (mood changes, bloating, breakthrough bleeding)
• Women whose clinician has assessed them as having a favorable cardiovascular risk profile (younger postmenopausal women, within 10 years of menopause onset, consistent with The Menopause Society's "timing hypothesis")
• Women at risk for osteoporosis who are also symptomatic (in the US, where the bone indication exists)

Women for Whom CE/BZA Is Not Appropriate

• Women with a history of breast cancer or undiagnosed breast mass
• Women with personal or family history of DVT or pulmonary embolism, or known thrombophilia
• Women with active liver disease or a history of cholestatic jaundice with prior estrogen use
• Women with known or suspected estrogen-dependent malignancies
• Any woman who is pregnant or planning to conceive (see below)
• Women without a uterus: estrogen-only therapy is simpler and has a longer evidence base; CE/BZA provides no additional benefit in this group

Pregnancy, Lactation, and Contraception

Duavee is contraindicated in pregnancy. This cannot be stated plainly enough. If you are pregnant or think you may be pregnant, do not take this drug.

Pregnancy Category and Human Data

The FDA assigned CE/BZA a Pregnancy Category X prior to the 2015 labeling change to the Pregnancy and Lactation Labeling Rule (PLLR) format. Under the current PLLR labeling, the prescribing information states that Duavee is contraindicated in pregnancy and that animal reproductive studies have shown fetal harm. Human data on CE/BZA in pregnancy are absent because the drug's indication is postmenopausal women, but the estrogenic and SERM components individually carry reproductive risks.

Bazedoxifene, as a SERM, has the potential for embryofetal toxicity consistent with other drugs in this class. Tamoxifen (a first-generation SERM) is a known teratogen, and raloxifene caused fetal harm in animal studies. The FDA label explicitly states that CE/BZA should not be used during pregnancy.

Who Might Be Prescribed This Drug and Still Be at Reproductive Risk?

CE/BZA is approved for postmenopausal women, and menopause is defined as 12 consecutive months without a period. But the perimenopausal transition can span years, and irregular cycles do not mean zero fertility. Clinicians occasionally see women in late perimenopause who believe they are postmenopausal but have residual ovarian function. Before prescribing CE/BZA, a clinician should confirm postmenopausal status with FSH and estradiol levels if there is any clinical uncertainty.

Lactation

CE/BZA is not intended for use in lactating women. Estrogens are known to suppress lactation by inhibiting prolactin-driven milk production. There are no data on bazedoxifene transfer into breast milk. Given the mechanism of action, lactation while taking CE/BZA is not recommended.

Contraception Requirements

Postmenopausal women do not require contraception by definition. However, a woman who has not yet reached confirmed menopause and who is prescribed CE/BZA off-label (which would be unusual and outside approved indications) would need effective non-hormonal contraception, because estrogen-progestogen oral contraceptives would be pharmacologically redundant and potentially antagonistic with bazedoxifene at the uterine receptor level.

Evidence Gaps: What We Still Do Not Know

Women have been historically under-represented in cardiovascular outcome trials, and CE/BZA is no exception to the broader problem.

The SMART program was designed to answer regulatory questions about efficacy and short-to-medium term endometrial safety. It was not powered to detect differences in:

• Breast cancer incidence over 10+ years
• Major adverse cardiovascular events (MACE) at a population level
• Cognitive outcomes (the WHI Memory Study used CE+MPA, not CE/BZA)
• All-cause mortality

The Menopause Society's 2023 position statement on hormone therapy acknowledges that the risk-benefit profile of HRT in general is most favorable when initiated in women under 60 or within 10 years of menopause onset, but it does not have specific long-term outcome data for the CE/BZA combination to cite separately from other HRT formulations. The statement treats CE/BZA as part of the broader HRT evidence base while noting that its progestogen-free design may have a distinct breast and metabolic profile.

The evidence gap on breast cancer is the one that matters most clinically. Until a dedicated long-term safety trial exists, clinicians are applying extrapolation from bazedoxifene's class and the SMART breast density data. This is a reasonable but explicitly not a fully evidenced position.

Comparing Regulatory Decisions: Why the Divergence?

The table below summarizes where CE/BZA stands globally and what a woman in each country can actually access.

| Country | Regulator | Status | Brand Name | Indication | |---|---|---|---|---| | United States | FDA | Approved (Oct 2013) | Duavee | VMS + osteoporosis prevention | | European Union | EMA | Approved (Dec 2014) | Duavive | VMS where progestogen not appropriate | | Canada | Health Canada | Not approved | N/A | N/A | | United Kingdom | MHRA | Not approved | N/A | N/A |

The US FDA and EU EMA both reviewed the SMART data and reached positive decisions, but with different indication wording. The FDA took the broader view, approving both the vasomotor and osteoporosis indications. The EMA was more restrictive in framing the indication as a second-line option.

Canada and the UK have not approved the combination. This is not a signal of safety concerns identified by Health Canada or the MHRA; neither agency has issued a rejection or a warning specific to CE/BZA. The absence of approval reflects the absence of a submitted marketing authorization application in those jurisdictions, a commercial rather than a safety decision by Pfizer.

The Menopause Society (formerly NAMS) 2023 position statement supports CE/BZA as "an effective and safe option for the management of bothersome VMS in postmenopausal women with a uterus," specifically noting it as a progestogen-free approach with established endometrial safety from the SMART program.

Practical Guidance: Getting a Prescription in the US and EU

In the United States, Duavee requires a prescription from a licensed prescriber. It is available at retail pharmacies and through telehealth platforms authorized to prescribe controlled and non-controlled medications in your state. Insurance coverage varies: as of 2024, many commercial plans cover Duavee at the same tier as other brand-name hormone therapies, but prior authorization may be required. A Pfizer savings card has been available for commercially insured patients, reducing out-of-pocket cost significantly.

In the EU, Duavive is available by prescription in countries where Pfizer has established distribution. Ask your gynecologist or general practitioner whether it is on the national formulary in your country. In Germany and France, it has been available and reimbursed under conditions; in smaller EU markets, availability may require a private prescription or import from another EU country under EU free movement of goods regulations.